Drug Comparison
For educational purposes only — a decision-support tool, not a substitute for clinical judgment.
Side-by-side rubric across 96 psychiatric medications. Every rating traces to a verbatim primary-source quote — click any cell to see it.
How to read this tool ▾
Rating scale
– Favorable / lower than class baseline
± Minimal / equivocal
+ Low / uncommon
++ Moderate / common
+++ High / very common
++++ Very high / class-outlier
Frequency vs severity
F = frequency, S = severity. Each gets its own pill colored on the same traffic-light scale: green → blue → yellow → orange → red. Click any cell for incidence percentages and NNH.
Evidence tier
A Network meta-analysis / RCT / FDA label
B Cohort / registry / pooled label data
C Expert review / textbook / case series
Sourcing
Click any cell to see the verbatim source quote and citation. Missing data shows n/a.
Data depth
++ Graded — frequency + severity, primary-source traces
+ FDA label — §6 frequency only (dashed border). Click for sub-types.
Blank — not yet checked (not “absent”)
–±++++++++++ABCF = frequency · S = severity · Dashed border = FDA label only · Click cell for details
1 drug selected — Vortioxetine(click to collapse)
1/4 selected
Vortioxetine
Trintellix
Serotonin Modulator and Stimulator
FDA-approved indications
- Major depressive disorder (adults)
Off-label uses
- Generalized anxiety disorder
- Cognitive dysfunction in MDD
Half-life66 hours
Decision GuideWhen to pick each / when to consider an alternative
Vortioxetine
Consider when
- Cognitive symptoms predominate — only antidepressant with significant objective cognitive improvement (DSST, TMT-B; g = −0.23 to −0.29)
- SSRI-induced sexual dysfunction has been a barrier — multimodal 5-HT1A agonism offsets SERT-driven SD; no CSFQ difference from placebo at 5–10 mg
- Top-tier efficacy and acceptability both desired — dual top-tier in Cipriani 2018 alongside escitalopram
- Discontinuation risk is a concern — ~66 h half-life provides self-taper; can stop abruptly without severe withdrawal
- +1 more
Consider an alternative when
- Nausea sensitivity — dose-dependent rates 21–32% at 5–20 mg vs 9% placebo; leading discontinuation cause
- Cost or formulary constraint — brand-only pricing at significant premium over generic SSRIs
- On strong CYP2D6 inhibitor or PM genotype — max 10 mg in PMs; dose halving required with paroxetine/fluoxetine/bupropion
- Broad indication coverage needed — MDD-only FDA approval; no anxiety, OCD, PTSD, or PMDD indications
- +1 more
Efficacy & Acceptability (1 axes)— NMA efficacy & discontinuation data (not side effects)
| Axis | Vortioxetine |
|---|---|
| 📊 Efficacy (response rates) | |
MDDEfficacy | |
| Axis | Vortioxetine SMS |
|---|---|
| Boxed Warnings | |
Suicidality (boxed warning) | |
Mania / hypomania induction | |
| CNS | |
Sedation / somnolence | |
Activation / insomnia | |
Seizure risk | |
| Metabolic | |
Weight loss | |
| Autonomic | |
Sweating | |
Angle-closure glaucoma | |
| GI | |
Nausea / GI (general) | |
| Electrolytes | |
Hyponatremia / SIADH | |
| Dermatologic | |
Rash (including SJS/TEN, pruritus, hypersensitivity) | |
| Sexual | |
Sexual dysfunction | |
| Discontinuation | |
Withdrawal / discontinuation | |
| Interactions | |
Serotonin syndrome risk | |
CYP interactions / DDI profile | |
| Safety | |
Bleeding risk | |
| Pregnancy | |
Lactation / breastfeeding safety | |
| Drug-specific / distinctive axes | |
Cardiovascular (HR + BP — favorable) only in Vortioxetine | |